Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 1993 Aug;11(8):1529-35.

Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.

Author information

  • 1University of Wisconsin Comprehensive Cancer Center, Madison.

Abstract

PURPOSE:

To determine the response rate of postmenopausal breast cancer patients to the gonadotropin-releasing hormone (GN-RH) agonist, Zoladex (goserelin; ICI Pharma, Wilmington, DE).

PATIENTS AND METHODS:

A multi-institutional single-agent trial in postmenopausal patients was conducted. Serum levels of follicle-stimulating hormone (FSH), testosterone, and estradiol were requested before and after Zoladex treatment.

RESULTS:

For estrogen receptor-positive (ER+) patients, the response rate was 11%, with one complete response (CR) and three partial responses (PRs) among 36 eligible patients. Responses were of short duration. There were no responses among 16 estrogen receptor-negative (ER-) patients.

CONCLUSION:

GN-RH agonists have activity in ER+ postmenopausal patients, but response rates are not as high as with other available endocrine therapies and the duration of response is short.

PMID:
8336191
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk